2026年11月3日星期二
M
寰宇通鑑
グローバル速報
Mitsubishi to sell part of stake in Canada LNG project to Blackstone funds— 日经 Nikkei AsiaJapan's SBI to invest in US digital bank Erebor, eyeing blockchain settlements— 日经 Nikkei AsiaAnthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaEU steps up subsea cable buildout to Japan and South Korea— 日经 Nikkei AsiaJapan's Don Quijote drops refund fees for tourists to boost spending— 日经 Nikkei AsiaVietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei AsiaMitsubishi to sell part of stake in Canada LNG project to Blackstone funds— 日经 Nikkei AsiaJapan's SBI to invest in US digital bank Erebor, eyeing blockchain settlements— 日经 Nikkei AsiaAnthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaEU steps up subsea cable buildout to Japan and South Korea— 日经 Nikkei AsiaJapan's Don Quijote drops refund fees for tourists to boost spending— 日经 Nikkei AsiaVietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei Asia

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

出典 Nature 医学研究23 時間前
内容の要約

当サイトはタイトルと要約のインデックスのみを提供しています。完全なコンテンツと著作権はすべて元の配信元に帰属します。原文リンクをクリックしてご覧ください。

原文へ
所属チャンネル
健康
所属地域
グローバル視点
原文の言語
English
項目番号
health-00a74bed

Comments 0 comments

No comments yet. Be the first.

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials · 寰宇通鑑